Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.49 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.42 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL429475 | 1.00 | CA2 (0.50) | CA2MAPK1NOD1GPR84FFAR1 | |
| SCHEMBL288045 | 1.00 | CA2 (0.50) | CA2MAPK1NOD1GPR84FFAR1 | |
| Hydrochloric Acid SCHEMBL4908040 | 0.98 | CA2 (0.48) | CA2MAPK1NOD1GPR84FFAR1 | |
| Hydrochloric Acid SCHEMBL20361641 | 0.98 | CA2 (0.48) | CA2MAPK1NOD1GPR84FFAR1 | |
| SCHEMBL24709075 | 0.93 | GPR84 (0.52) | CA2MAPK1NOD1GPR84FFAR1 | |
| SCHEMBL21102191 | 0.93 | GPR84 (0.52) | CA2MAPK1NOD1GPR84FFAR1 | |
| SCHEMBL15451410 | 0.93 | GPR84 (0.52) | CA2MAPK1NOD1GPR84FFAR1 | |
| SCHEMBL20366017 | 0.91 | GPR84 (0.55) | NOD1GPR84FFAR1MAPTLCK | |
| SCHEMBL25208251 | 0.91 | GPR84 (0.55) | NOD1GPR84FFAR1MAPTLCK | |
| SCHEMBL3896154 | 0.91 | GPR84 (0.55) | NOD1GPR84FFAR1MAPTLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3578 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015393-A1 | NOVEL NMU RECEPTOR 2 AGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2026-01-15 | — | — | US | claimed |
| US-20250296959-A1 | B7-H3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | MARIANA ONCOLOGY INC (US) | 2025-09-25 | — | — | US | claimed |
| EP-4590347-A1 | NOVEL MINIGASTRIN-DERIVED CHOLECYSTOKININ 2 RECEPTOR BINDING MOLECULES FOR IMAGING AND TARGETED RADIOTHERAPY | Technische Universität München (DE) | 2025-07-30 | — | — | EP | claimed |
| US-20250222146-A1 | Radiopharmaceuticals Targeting Somatostatin Receptor 2 and Uses Thereof | RAYZEBIO, INC. (US) | 2025-07-10 | — | — | US | claimed |
| WO-2025137441-A1 | RADIOPHARMACEUTICALS TARGETING SOMATOSTATIN RECEPTOR 2 AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-06-26 | — | — | WO | claimed |
| WO-2025109003-A1 | P-CADHERIN LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-05-30 | — | — | WO | claimed |
| US-20250161408-A1 | PEPTIDIC INHIBITORS OF AMYLOID SELF- AND CROSS-ASSEMBLY | LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) | 2025-05-22 | — | — | US | claimed |
| WO-2025100520-A1 | PEPTIDE, PEPTIDE COMPLEX, PHARMACEUTICAL COMPOSITION, COMPOSITION FOR CELL CULTURE, AND COMPOSITION FOR MEDICAL USE, DIAGNOSTIC USE, OR RESEARCH USE | ペプチドリーム株式会社 | 2025-05-15 | — | — | WO | claimed |
| US-20250049970-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | MARIANA ONCOLOGY INC (US) | 2025-02-13 | — | — | US | claimed |
| US-20250034210-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | MARIANA ONCOLOGY INC (US) | 2025-01-30 | — | — | US | claimed |
| WO-2005073164-A1 | THERAPEUTIC AND CARRIER MOLECULES | PEPLIN BIOLIPIDS PTY LTD (AU) | 2005-08-11 | — | — | WO | claimed |
| EP-1506221-A2 | FAP-ACTIVATED ANTI-TUMOR PRODRUGS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2005-02-16 | — | — | EP | claimed |
| EP-1472277-A1 | FAP-ACTIVATED ANTI-TUMOR COMPOUNDS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-11-03 | — | — | EP | claimed |
| US-20040033957-A1 | FAP-activated anti-tumor prodrugs | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-02-19 | — | — | US | claimed |
| WO-2003094972-A2 | FAP-ACTIVATED ANTI-TUMOR PRODRUGS | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) | 2003-11-20 | — | — | WO | claimed |
| US-20030211979-A1 | FAP-activated anti-tumor compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-11-13 | — | — | US | claimed |
| WO-2003064454-A1 | FAP-ACTIVATED ANTI-TUMOR COMPOUNDS | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) | 2003-08-07 | — | — | WO | claimed |
| EP-1333033-A1 | FAP-activated anti-tumor compounds | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-08-06 | — | — | EP | claimed |
| EP-0655463-A1 | Cyclic hexapeptides having endothelin antagonistic activity | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-05-31 | — | — | EP | claimed |
| WO-1993000359-A1 | MODIFIED PEPTIDES TRANSPORTABLE INTO THE CENTRAL NERVOUS SYSTEM | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-01-07 | — | — | WO | claimed |